Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell?

Shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) dropped 2.5% on Monday . The stock traded as low as $2.20 and last traded at $2.33. Approximately 43,364 shares were traded during mid-day trading, a decline of 21% from the average daily volume of 55,007 shares. The stock had previously closed at $2.39.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ALZN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alzamend Neuro in a research note on Monday, December 29th. Ascendiant Capital Markets lowered their target price on Alzamend Neuro from $42.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $28.00.

Alzamend Neuro Stock Performance

The company has a market capitalization of $8.85 million, a price-to-earnings ratio of -0.71 and a beta of -0.25. The company’s fifty day simple moving average is $2.18 and its two-hundred day simple moving average is $2.42.

Alzamend Neuro (NASDAQ:ALZN) last issued its earnings results on Tuesday, December 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.53. Sell-side analysts anticipate that Alzamend Neuro, Inc. will post -1.68 EPS for the current year.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.